Here’s a quick look at 6 notable things that happened in medicine very recently.
Treatment-resistant major depression in older people is widespread and potentially life-threatening. This NIH-sponsored trial evaluated the efficacy and safety of augmentation therapy with the antipsychotic agent aripiprazole (Abilify) in 181 patients with treatment-resistant depression who had not achieved pre-trial remission with venlafaxine XR (Effexor).
Lenze EJ, et al. The Lancet. September 2015 DOI: 10.1016/S0140-6736(15)00308-6.Â©morrison/Shutterstock.com
The approval of flibanserin for hypoactive sexual desire disorder in premenopausal women met with a mixed review. Here’s a small sampling.
Here's a study of the cardiovascular effects of empagliflozin (Jardiance). In 7020 high risk adults with comorbid T2 diabetes and CV disease, who were randomly assigned to 10 mg or 25 mg of empagliflozin or placebo once daily and followed for a mean of 3.1 years. Empagliflozin recipients had significantly lower rates of the primary composite CV outcome and of death from any cause when study drugs were added to standard care.
Zinman B, et al. NEJM. Sept 17, 2015. Â©Sebastian Kaulitzsky/Shutterstock.com
The FDA has just approved Durlaza, a 24-hour XR aspirin formulation for secondary prevention of stroke and acute cardiac events. Details, here.Â©kwittybear/Shutterstock.com
In 2014, the Federal Trade Commission reported that there were 29 "pay-for-delay" agreements involving 21 different brand names.Details, here.Â©Sergey Nivens/Shutterstock.com
In this slide show, you’ll find quick summaries of notable things that happened in the world of medicine this month. Special thanks to David J. Bromberg, MD.